Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 01022024150106
Smart Chart Mental and Behavioral Health Look Forward to Transforming the Patient Journey in Mental Health December 14, 2023
Video / Webinar Life Sciences & Pharma L.E.K. Look Forward - L.E.K. Talent Focused Organisational Strategy December 13, 2023
Article Life Sciences & Pharma The SEA Healthcare, Medtech, and Pharma Landscape in 2023 December 7, 2023
Executive Insights Life Sciences & Pharma Creating Opportunities and Avoiding Missteps in Biopharma Supply Chain Strategy June 26, 2023
Article Healthcare Services The LatAm Digital Landscape in Healthcare: Where Are the Opportunities Today? April 25, 2023